x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The BioHub: The Top Voices in Biotech

Max Brennan - Biotech HeadHunter

Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape. Subscribe now and be part of the conversation that"s shaping the future of biotechnology. Get ready for an immersive

science life sciences

All Episodes

00:31:46

Episode 123 - Adam Mendelsohn - CEO Vivani Medical

The BioHub: The Top Voices in Biotech ·

2026/02/25

In this episode of The BioHub, I’m joined by Dr. Adam Mendelsohn, Co-Founder and CEO of Vivani Medical.Adam’s journey spans bioengineering at UCSF and UC Berkeley to founding Nano Precision Medical and now leading Vivani following its 2022 merger. Vivani is developing long-term, sub-dermal drug implants designed to transform treatment for chronic diseases such as obesity and diabetes.We discuss the science behind the platform, why long-acting implants could shift the treatment paradigm, what’s

en

00:24:13

Episode 122 - Todd Zavodnick - CEO of Excellergy

The BioHub: The Top Voices in Biotech ·

2026/02/24

🎙 New Episode Live – Todd Zavodnick, CEO of ExcellergyTodd Zavodnick is the CEO of Excellergy, a clinical-stage biotechnology company redefining allergy treatment. Their mission? To make therapies faster, more effective, and far more convenient for patients — transforming the experience of managing allergies.Before Excellergy, Todd built a track record of leadership in biotech, bringing together scientific rigor and strategic vision to tackle complex challenges in patient care.In this episode, we

en

00:36:30

Episode 121 - Terry Rosen: CEO & Co-Founder of Arcus...

The BioHub: The Top Voices in Biotech ·

2026/02/19

Today’s guest is Terry J. Rosen, a scientist-entrepreneur who has helped shape the modern era of cancer immunotherapy.Dr. Rosen is the co-founder and CEO of Arcus Biosciences, a clinical-stage biotechnology company focused on developing innovative immuno-oncology therapies and combination treatments designed to transform outcomes for patients with cancer. Before launching Arcus, he co-founded Flexus Biosciences, which was acquired by Bristol-Myers Squibb in 2015—an early validation of his vision in

en

00:23:36

Episode 120 - Thijs Spoor - CEO Perspective Therapeutics

The BioHub: The Top Voices in Biotech ·

2026/02/18

In this episode of The BioHub, I’m joined by Thijs Spoor, CEO of Perspective Therapeutics.Thijs has taken an unconventional path to the CEO seat, bringing decades of leadership experience across healthcare and capital markets into one of the most exciting areas of biotech: targeted radiopharmaceuticals.We talk about his journey into the industry, the science and vision behind Perspective, the company’s recent $175M raise, and the milestones that could define their next phase of growth. A great

en

00:24:00

Episode 119 - Erik van den Berg - CEO of Memo...

The BioHub: The Top Voices in Biotech ·

2026/02/16

Prior to JPM 2026 and the news of their recent CSL collaboration, I spoke to Memo Therapeutics' CEO, Erik van den Berg for an episode of The BioHub Podcast.Memo are preparing for a global ph3 trial of Potravitug, their antibody against BK polyomavirus infection in kidney transplant recipients. BKPyV infection can lead to nephropathy, loss of kidney function, as well as organ failure, rejection & death, with the virus residing in up to 90% of the total population.Erik joins us to walk through

en

00:29:10

Episode 118 - Declan Doogan - CEO & Executive...

The BioHub: The Top Voices in Biotech ·

2026/02/12

We were delighted to welcome Declan Doogan, CEO of Causeway Therapeutics, onto The BioHub! Declan is a highly respected leader in the biopharmaceutical industry, with decades of experience spanning drug development, clinical research, and executive leadership at some of the world’s leading pharmaceutical companies.Throughout his career, he has played a pivotal role in advancing innovative therapies from early discovery through to global commercialization. At Causeway Therapeutics, he is leading the

en

00:35:10

Episode 117 - Raj Devraj - CEO Rectify Pharma

The BioHub: The Top Voices in Biotech ·

2026/02/11

In this episode of The BioHub, I’m joined by Raj Devraj, CEO of Rectify Pharma and Venture Partner at Atlas Venture.Raj has spent his career building biotech companies around bold science, including co-founding Disarm Therapeutics, which was acquired by Eli Lilly. Now he’s doing it again with Rectify.We talk about starting companies from zero, building the right teams early, de-risking new ventures, and the realities of fundraising in today’s biotech market. A practical, honest conversation with a

en

00:24:04

Episode 116 - Jim Jenson - Morphoceuticals

The BioHub: The Top Voices in Biotech ·

2026/02/10

We were delighted to Welcome Jim Jenson, CEO of Morphoecueticals a TechBio company focused on understanding and manipulating the bioelectrome to induce regeneration and treat disease.

en

00:24:30

Episode 115 - Simeon George - CEO & Co-Founder of SR...

The BioHub: The Top Voices in Biotech ·

2026/02/10

We were delighted to welcome Simeon George, the CEO and Managing Partner of SR One Capital Management, a global biotech venture capital firm he helped spin out of GSK, onto the BioHub! He’s a physician by training, with an MD from the University of Pennsylvania, an MBA from Wharton, and a background that also includes time at Bain & Company and Goldman Sachs.Over the years, Simeon has helped build and back some of the most impactful companies in modern biotech, including CRISPR Therapeutics,

en

00:35:50

Episode 114 - Martijn Negen - COO of VarmX

The BioHub: The Top Voices in Biotech ·

2026/02/09

We're joined by Martijn for an engaging discussion on VarmX's latest milestones & the wider biotech market.In Q4 2025, VarmX signed a strategic collaboration with CSL to fully fund a global ph3 trial & pre-launch readiness for their lead asset VMX-C001 - a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs. Martijn shares insight on how the deal came about, what it could mean for patients and VarmX

en

00:39:40

Episode 113 - Kim Hazen- Chief People Officer at...

The BioHub: The Top Voices in Biotech ·

2026/02/05

Today’s guest is Kim Hazen, a seasoned people and culture leader with more than two decades of experience shaping organizations at the intersection of science, business, and talent.Kim is currently the Chief People Officer at Fulcrum Therapeutics, where she leads human resources and culture for a clinical-stage biotech company focused on developing treatments for rare genetic diseases. Over the course of her career, she’s built and scaled people strategies across both life sciences and financial

en

00:29:10

Episode 112 - Rodolphe Clerval - CEO of Coave...

The BioHub: The Top Voices in Biotech ·

2026/02/04

In this episode of The BioHub, I’m joined by Rodolphe Clerval, CEO of Coave Therapeutics.Rodolphe’s journey into the CEO seat wasn’t a traditional one. He moved from science into investment banking, then into major business development roles, before stepping into leadership at multiple biotech companies.We talk about that unconventional path, the story behind Coave’s evolution and rebrand, and why their precision gene therapy approach is so exciting. It’s a thoughtful conversation about mindset,

en

00:34:21

Episode 111 - Kevin Pojasek - President and CEO of...

The BioHub: The Top Voices in Biotech ·

2026/02/03

We were delighted to be joined by Kevin Pojasek who's the President and CEO of Enara Bio.Enara Bio is shining a light on Dark Antigen and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients with solid tumors. There pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for

en

00:07:25

Episode 110 - JPM Special - Maureen Hillenmeyer - CEO...

The BioHub: The Top Voices in Biotech ·

2026/01/28

JPM Special — Maureen Hillenmeyer, CEO & Founder of Hexagon BioIn this JPM Special episode of The BioHub, I’m joined by Maureen Hillenmeyer, CEO and Founder of Hexagon Bio.Maureen has built Hexagon around a bold idea: using genomics, computation, and the biology of natural products to unlock entirely new medicines. At JPM, we sat down to talk about what it really takes to build a platform company in today’s market — from scientific conviction and capital discipline to leadership, culture, and

en

00:31:44

Episode 109 - Mike Exton - CEO Lexicon Pharma

The BioHub: The Top Voices in Biotech ·

2026/01/26

I’m here with Mike Exton, the CEO of LexiconPharmaceuticals.Mike joined Lexicon in 2024 after two decades of leadershipacross Novartis and Eli Lilly, where he helped launch some of the biggest cardiovascular drugs in the world — including Entresto.Now he’s leading Lexicon through a bold new chapter, with agenomics-driven pipeline focused on cardiometabolism and neuroscience, and a strategy built around delivering best-in-class or first-in-class medicines in areas of real unmet need.Mike, great to

en

00:11:47

Episode 108 - JPM Special - Dirk Thye, CEO Quince...

The BioHub: The Top Voices in Biotech ·

2026/01/26

In our first JPM Special 2026, we’re joined by Dirk Thye, CEO of Quince Therapeutics, as the company approaches a defining Phase 3 readout. A candid conversation about high-stakes data, leadership under pressure, and what a true do-or-die moment looks like in biotech.

en

00:30:16

Episode 107- Kevin Marks - CEO Delphia Therapeutics

The BioHub: The Top Voices in Biotech ·

2026/01/22

Today’s guest is Kevin Marks, a biotech entrepreneur and the founder and CEO of Delphia Therapeutics. Kevin has spent his career at the forefront of cancer drug discovery, working across research, strategy, and company building with a singular focus on translating breakthrough science into meaningful medicines for patients. Before founding Delphia, he built deep experience in oncology and precision medicine, helping advance novel therapeutic programs and navigating the complex path from early

en

00:21:22

Episode 106 - Gemma Guinart Mola - Principal at...

The BioHub: The Top Voices in Biotech ·

2026/01/20

On this episode we're joined by Invivo Partners' Gemma Guinart, for a discussion into early-stage biotech investing.Invivo Partners look to invest in compelling in-vivo proof of concept data, and back founding teams across Europe with pre-seed to Series A investment - recent investments from their third fund include Neumirna Tx & Signadori Bio.Tune in to hear more about how Gemma & the team identify investment opportunities & why they focus on early-stage investments in a market

en

00:24:08

Episode 105 - Ahmet Tutuncu - CEO of AeroRx Therapeutics

The BioHub: The Top Voices in Biotech ·

2026/01/15

We're joined by Ahmet Tutuncu, CEO of AeroRx Therapeutics, to discuss their novel, best-in-class nebulized combination product for moderate-to-severe COPD patients. AeroRx's pipeline includes AERO-007, the first nebulized LABA/LAMA combination in clinical development, and AERO-111, the first triple LABA/LAMA/ICS nebulized therapy in IND-enabling studies. Ahmet previously co-founded Elevation Pharma and Patara Pharma, both acquired for their inhaled-drug platforms. In a wide ranging

en

00:19:58

Episode 104 - Amir Hefni - CEO of Resolution...

The BioHub: The Top Voices in Biotech ·

2026/01/05

On this episode we feature the CEO of Resolution Therapeutics, Amir Hefni. Throughout his career, Amir has held roles with global powerhouses such as BMS, Ipsen, & Novartis, before transitioning to small biotech with Resolution in 2023.Resolution's pipeline of regenerative macrophage therapies originates from research out of Edinburgh University. With potential across inflammatory & fibrotic diseases, the team are currently focused on patients with end-stage liver cirrhosis who otherwise

en

149 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter